Rights and permissions
About this article
Cite this article
Oxybutynin ER better value than tolterodine IR for overactive bladder. Pharmacoecon. Outcomes News 447, 12 (2004). https://doi.org/10.2165/00151234-200404470-00028
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200404470-00028